Skip to main content

Biglari Holdings Inc.

For the period ended Mar 31, 2025. Filed May 9, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

BH$349.22-6.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Earnings — First Quarter 2025 and 2024

CONSOLIDATED STATEMENTS OF EARNINGS

(dollars in thousands except per share amounts)

First Quarter
20252024
(Unaudited)
Revenues
Restaurant operations$64,349$61,996
Insurance premiums and other19,34917,733
Oil and gas9,9309,510
Licensing and media1,407212
Total revenues95,03589,451
Costs and expenses
Restaurant cost of sales37,75834,421
Insurance losses and underwriting expenses17,05215,063
Oil and gas production costs4,0464,499
Licensing and media costs1,651503
Selling, general and administrative21,36718,275
Gain on sale of oil and gas properties(9,323)(481)
Impairments—107
Depreciation, depletion, and amortization10,25710,053
Interest expense on leases1,3331,314
Interest expense on debt900—
Total costs and expenses85,04183,754
Other income
Investment gains (losses)(1,585)1,713
Investment partnership gains (losses)(49,592)21,985
Total other income (expense)(51,177)23,698
Earnings (loss) before income taxes(41,183)29,395
Income tax expense (benefit)(7,908)6,816
Net earnings (loss)$(33,275)$22,579
Net earnings (loss) per average equivalent Class A share*$(126.40)$79.56

*Net earnings (loss) per average equivalent Class B share outstanding are one-fifth of the average equivalent Class A share or $(25.28) for the first quarter of 2025 and $15.91 for the first quarter of 2024.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.